New Hope for Treating Neurodegenerative Diseases
(NAPSI)—Scientists have searched for decades without success for ways to repair the devastating damage caused by neurodegenerative diseases, but there are now new compounds in clinical development that offer hope.
The Problem
When there is a mass die-off of neurons in the body, the central nervous system misfires like a faulty circuit board—one that cannot be fixed without replacing the blown fuses. This major physiological malfunction tends to trigger the onset of some of the hardest-to-treat neurodegenerative diseases, including Alzheimer’s disease and multiple sclerosis (MS).
These are terrible afflictions that affect millions of North Americans. They also cost the healthcare system billions of dollars a year, mostly spent on managing physical and mentally debilitating symptoms that inexorably get worse.
What’s more, current treatments can only “modify” (slow down or mitigate) the destructive effects on the human body caused by the mass death of neurons in the brain or spine.
The Search For A Solution
With that all said, many people may be relieved to learn of a small Canadian-headquartered biotech start-up that offers new hope to tens of millions of sufferers of neurodegenerative diseases. With Phase 1 clinical trials already underway, NervGen Pharma believes it’s on-track to become a big breakthrough thanks to its blockbuster drug candidate—NVG-291.
NVG-291 is a peptide (a small protein) that works by targeting the protein tyrosine phosphatase sigma (PTP?) receptor that blocks nerve repair following injury, whether from trauma or conditions such as MS or Alzheimer’s disease. NervGen targets nerve cell repair, while promoting plasticity to create new neural pathways.
NVG-291 is the brainchild of Dr. Jerry Silver, a renowned spinal cord injury and regenerative medicine researcher whose pioneering work addresses a diversity of conditions defined by a damaged central nervous system. These include degenerative diseases, spinal cord damage, stroke and traumatic brain injury.
Researchers are currently conducting trials in healthy volunteers. This will transition to studies for several of these medical aliments. In particular, the company has stepped up its interest in NVG-291’s ability to tackle Alzheimer’s disease.
The company works with Dr. Ksenia Kastanenka of Massachusetts General Hospital—which has a long history of supporting cutting-edge research and innovation in medical research—to study NVG-291 in animal models of Alzheimer’s disease.
It’s also preparing to enter a Phase 1b clinical trial for Alzheimer’s patients in 2022 following ongoing Phase 1 safety trials for the drug candidate.
An Expert’s Opinion
According to NervGen’s CEO, Paul Brennan, “The multiple preclinical studies that we are conducting, as well as our planned Phase 1b study, are important milestones for our Alzheimer’s program, which, if successful, will provide a meaningful benefit to patients and significant potential for NervGen.
“What differentiates NVG-291 from other drugs in development is that it leverages multiple mechanisms for repairing nerve damage, while most others focus on a single approach. Alzheimer’s disease is a complex condition and likely caused by multiple factors. We believe that a systems approach to treating the disease is an important distinction.”
Brennan adds, “All told, NVG-291’s ability to remyelinate and enhance plasticity is a one-two knockout punch for repairing a damaged central nervous system, which is the end result on a diversity of neurodegenerative diseases, as well as traumatic brain and spinal injuries. NVG-291 could herald a revolutionary new paradigm in treating all of these chronically debilitating conditions.”
The company’s continued strides toward launching this new class of drugs offers renewed hope to millions.
Learn More
For further facts on the research and clinical trials, go to www.nervgen.com.
On the Net:North American Precis Syndicate, Inc.(NAPSI)
Get Top Stories Delivered Weekly
Recent thebridgenewspaper News Articles
Discuss This Article
MOST POPULAR THEBRIDGENEWSPAPER
Top 5 Essential College Apps By Tina Gomez, Senior Reporter
Donuts a Call Away By Tina Gomez, Senior Report
FEAR is Coming By Judith Mae Aguilar, Senior Reporter
New Options for Laredo Foodies By Judith Mae Aguilar, Senior Reporter
GET TOP STORIES DELIVERED WEEKLY
FOLLOW OUR NEWSPAPER
LATEST THEBRIDGENEWSPAPER
RECENT THEBRIDGENEWSPAPER CLASSIFIEDS
OUTSIDE THE LINES
- A Story To Sing About
- The Gap in Gum Care: Why Caring For Your Teeth’s F...
- Top Tips for Signature Scents and Better-Smelling Laundry
- A Dog Trainer’s Top Tips to Support Pets Through Life S...
- Clear the Air of Indoor Pollutants This Spring
- Stroke & Dementia in Black Men: Tips for Staying Healthy...
- Hispanics and African Americans at Higher Risk for Eye...
- African Americans at Higher Risk for Eye Disease
- Infinity Kings: Final Book In A Favorite Fantasy Series
- What You Need To Know About Keratoconus and the iLink...
FROM AROUND THE WEB
- Don’t Let Diabetes Shortchange Your Golden Years
- No Child is Forgotten By Marine Toys for Tots
- Sweeten Your Springtime Salads With Healthy Chilean Grapes
- Young Author Translates 4,000-Year-Old Text to Reveal...
- Keeping Cool and Energy-efficient Amid America’s “...
- Addressing Sarcopenia with a Healthy Diet
- Subway’s New Wraps Elevate Eating on the Go
- Family Teacher Conference Topics Beyond Academics
- Youth Take Down Tobacco
- BookTrib’s Bites: Four Reads to Kickoff Spring